Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.
AstraZeneca’s trial lives up to its billing, though the benefit might be subgroup-driven, and comes at the cost of toxicity.
Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.
One first-in-human study and two deals in a single day sees companies blaze the ADC trail.
CuraDev and OncoNano move into phase 1, trying to avoid the negative precedent of other Sting agonist projects.
Seagen/Genmab’s confirmatory cervical cancer trial is toplined positive, putting up a fresh roadblock for Iovance’s accelerated filing plans.